We are live on ! Find out more
CYTO icon

Altamira Therapeutics Ltd

Delisted

CYTO was delisted on the 19th of December, 2024.

6 hedge funds and large institutions have $443K invested in Altamira Therapeutics Ltd in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,646% more capital inflows, than outflows

Capital inflows: $159K | Capital outflows: $1.36K

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more funds holding

Funds holding: 3 → 6 (+3)

3.98% more ownership

Funds ownership: 7.69% → 11.66% (+4%)

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CYTO Hedge Fund Activity: Q4 2019 in Review

6 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2019, worth a combined $443K — down 11% from $497K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CYTO positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $77.3K. The largest seller was UBS Group, exiting entirely with an estimated $1.36K sold.

  • 6 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2019, up from 3 in Q3 2019.
  • Funds reported $443K of Altamira Therapeutics Ltd stock for Q4 2019, down 11% quarter-over-quarter.
  • 4 funds opened new Altamira Therapeutics Ltd positions in Q4 2019 and 1 closed out, a net change of +3 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q4 2019 was Renaissance Technologies, an estimated $77.3K added.
  • The largest Altamira Therapeutics Ltd seller in Q4 2019 was UBS Group, an estimated $1.36K sold.

Based on aggregated 13F filings for Q4 2019.